ZS Pharma Inc., of Redwood City, Calif., published previously unreleased data about its lead candidate, ZS-9, in a letter to the editor of The New England Journal of Medicine describing a combined analysis of two phase III patients with severe hyperkalemia who received a 10-mg dose of the drug, leading to a "rapid and clinically significant reduction in potassium as early as one hour after administration."